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Surgical site occurrence 
A B S T R A C T   
Background: Resorbable biomaterials have been developed to reduce the amount of foreign material remaining in 
the body after hernia repair over the long-term. However, on the short-term, these resorbable materials should 
render acceptable results with regard to complications, infections, and reoperations to be considered for repair. 
Additionally, the rate of resorption should not be any faster than collagen deposition and maturation; leading to 
early hernia recurrence. Therefore, the objective of this study was to collect data on the short-term performance 
of a new resorbable biosynthetic mesh (Phasix™) in patients requiring Ventral Hernia Working Group (VHWG) 
Grade 3 midline incisional hernia repair. 
Materials and methods: A prospective, multi-center, single-arm trial was conducted at surgical departments in 15 
hospitals across Europe. Patients aged ≥18, scheduled to undergo elective Ventral Hernia Working Group Grade 
3 hernia repair of a hernia larger than 10 cm2 were included. Hernia repair was performed with Phasix™ Mesh in 
sublay position when achievable. The primary outcome was the rate of surgical site occurrence (SSO), including 
infections, that required intervention until 3 months after repair. 
Results: In total, 84 patients were treated with Phasix™ Mesh. Twenty-two patients (26.2%) developed 32 sur-
gical site occurrences. These included 11 surgical site infections, 9 wound dehiscences, 7 seromas, 2 hematomas, 
2 skin necroses, and 1 fistula. No significant differences in surgical site occurrence development were found 
between groups repaired with or without component separation technique, and between clean-contaminated or 
contaminated wound sites. At three months, there were no hernia recurrences. 
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Conclusion: Phasix™ Mesh demonstrated acceptable postoperative surgical site occurrence rates in patients with 
a Ventral Hernia Working Group Grade 3 hernia. Longer follow-up is needed to evaluate the recurrence rate and 
the effects on quality of life. This study is ongoing through 24 months of follow-up.   
1. Introduction 
Incisional hernia (IH) is a frequent complication after abdominal 
surgery, with incidences varying from 10 to 20% [1], and can be more 
than 30% in high-risk patients, such as patients with a Body Mass Index 
(BMI) over 30 kg/m2 [2,3]. Patients with IH score lower in the areas of 
physical functioning, cosmetic, and body image components of 
health-related quality of life questionnaires [4]. Surgical hernia repair is 
often needed as a result; some 350,000 ventral hernia repairs are done 
each year in the Unites States alone [5]. 
Incisional hernias used to be repaired with sutures only. However, 
multiple studies have shown that repair with synthetic mesh leads to 
significantly fewer recurrences compared to primary suture repair [1, 
6–8]. However, permanent synthetic mesh has also been associated with 
chronic inflammation, pain, adhesions, and fistulae [6,9]. With a re-
ported infection rate of about 5%, synthetic meshes are more prone to 
infection than biological tissue-derived materials [10]. This could pose a 
problem in potentially contaminated hernias like Ventral Hernia 
Working Group (VHWG) Grade 3 hernias (Table 1) [11]. The success of 
the mesh repair is jeopardized by potential contamination, which is 
caused by complicating factors such as previous wound infection, the 
presence of a stoma or violation of the gastro-intestinal tract. 
Due to this potential contamination in VHWG Grade 3 hernias, it may 
be desirable that no foreign material remains in the body: that the mesh 
is resorbed. An alternative to permanent synthetic mesh, such as bio-
logical tissue-derived materials, may be considered. It is hypothesized 
that biological meshes have a higher ability to resist infection, have a 
milder inflammatory response, and cause more orderly collagen depo-
sition than permanent synthetic meshes [12–14]. However, these bio-
logical materials are costly, and have not fulfilled all expectations 
related to their possible advantages. 
A more recent development in surgical prostheses is biosynthetic 
mesh. Biosynthetic mesh made from poly-4-hydroxybutyrate (P4HB) 
has the advantage of having mechanical strength comparable to tradi-
tional polypropylene mesh [15], and might therefore result in low 
recurrence rates when used for incisional hernia repair. Additionally, it 
resorbs over 12–18 months [15,16], leaving no foreign material behind 
in the body. However, this P4HB mesh retains only 70% of its strength 
after 12 weeks [15,17,18], possibly causing early hernia recurrence due 
to early breakdown of the mesh. Also its ability to resist infection in 
potentially contaminated sites (such as VWHG grade 3 hernias) remains 
understudied. For such a new and promising mesh to be considered for 
repair, postoperative complication and infection rates should be 
collected. The objective of this study was therefore to collect additional 
data on the short-term performance of a P4HB synthetic mesh (Phasix™) 
in patients requiring VHWG Grade 3 midline incisional hernia repair. 
2. Methods 
2.1. Study design 
This prospective, single-arm, multicenter trial was conducted at 
surgical departments in 15 hospitals across Europe. The trial protocol 
has been previously published [19] and can be found on clinicaltrials. 
gov (NCT02720042). Patients aged 18 years or older and scheduled to 
undergo elective VHWG Grade 3 hernia repair of a midline incisional 
hernia larger than 10 cm2 were asked to participate in the trial. Patients 
with a BMI over 35 kg/m2, peritonitis, HIV, liver cirrhosis, or chemo-
therapeutic medication were excluded. An elaborate overview of 
exclusion criteria has been previously published [19]. 
The protocol was reviewed and approved by the Institutional Review 
Boards or Health Authorities of all participating centers. All participants 
gave written informed consent prior to any study procedures being 
conducted. The study has been reported following the STROCSS criteria 
[20]. 
2.2. Procedures 
The participants were registered in an online database with a per-
sonal, unique trial code. Final eligibility of a patient, with regard to the 
hernia-specific and intraoperative exclusion criteria, was determined 
during surgery. 
All eligible patients underwent open ventral hernia repair. The 
Phasix™ Mesh had to be placed in a retro-rectus (sublay) position. Onlay 
placement was allowed only when retro-rectus placement could not be 
achieved. The Phasix™ Mesh was fixated with slowly resorbable sutures. 
The specific type of suture and fixation pattern were left to the discretion 
of the surgeon, along with the use of component separation technique 
(CST), when considered appropriate. The mesh was positioned to 
overlap the defect on all edges by at least 5 cm. It was recommended to 
the surgeons to fixate the mesh at approximately 5–6 cm-intervals 
around the periphery of the mesh. All skin incisions were closed with 
staples or sutures. 
After surgery, patients were treated per hospitals’ standard protocol. 
Patients were invited for follow-up visits on three points in time: after 
drain removal or at hospital discharge, 1 month after surgery, and 3 
months (±14 days) after surgery. During these follow-up visits – as well 
as before surgery – patients underwent physical examination by a 
medical doctor. 
2.3. Outcomes 
The primary outcome was surgical site occurrence (SSO) that 
required any type of medical or surgical intervention. SSOs were 
assessed by physical examination at each study visit through 3 months 
(±14 days). SSO was defined as hematoma, seroma, surgical site infec-
tion (SSI) [21], wound dehiscence, skin necrosis and fistula. As a sec-
ondary endpoint, the hernia recurrence rate up until 3 months was 
assessed. 
2.4. Statistical analysis 
Since VHWG grade 3 hernia patients are rare, it was chosen to use a 
sample of convenience. Seventy-five patients were deemed sufficient to 
evaluate the performance of Phasix™ Mesh. This means that at an 
estimated SSO rate at 3 months of 37% [22–25], the accuracy will be 
11% (i.e. half of the 95% Confidence Interval width of the estimated SSO 
Table 1 
Ventral Hernia Working Group grading system: assessment of risk for surgical 
site occurrences [11].  
Grade 1 Grade 2 Grade 3 Grade 4 
Low Risk Co-morbid Potentially 
contaminated 
Infected 
Low risk of 
complications 
















COPD: chronic obstructive pulmonary disease, GI: gastro-intestinal. 
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rate, is 11%). Eighty-five participants were included due to an antici-
pated attrition rate of approximately 10%. 
Data from all patients in whom Phasix™ Mesh was implanted were 
analyzed, through an intention-to-treat principle. No missing value 
imputation methods were applied. Patient and hernia characteristics 
were summarized with frequency counts and percentages, or with the 
mean and standard deviation (SD). Information on follow-up is given 
through median and interquartile range (IQR), and the primary 
endpoint is reported with a 95% confidence interval (CI). 
3. Results 
In total, 85 patients were enrolled in the study between March 2016 
and April 2017. In one patient, a different type of mesh was implanted. 
Therefore, 84 patients were included in the analysis. All but 1 patient 
attended their follow-up visits up to and including the 3-month visit 
(median follow-up 90 days, interquartile range 85–99 days). 
3.1. Patients and follow-up 
Baseline characteristics are listed in Table 2. The mean age in males 
was 63.3 years (SD 12.8) and in females 61.3 years (SD 11.9). The mean 
BMI in males was 27.4 kg/m2 (SD 3.6) and in females 28.3 kg/m2 (SD 
4.6). Twenty-five patients (29.8%) had other significant medical history 
not listed in Table 3, such as an intersphincteric fistula, Crohn’s disease, 
pancreatitis, depression, hip replacement, cholecystectomy, or post- 
traumatic stress syndrome, among others. 
3.2. Hernia and surgery characteristics 
Sixty-eight patients (81%) were operated on for a primary incisional 
hernia, 9 patients (10.7%) were operated for a first-time recurrence, and 
for 7 patients (8.4%) it was a repair of ≥second-time recurrence. Of the 16 
patients (19.1%) who were operated on for incisional hernia recurrence, 
10 (11.9%) had a previously placed mesh that needed to be explanted. 
Reasons for VHWG 3 classification were previous wound infections 
in 51 patients (60.7%), stoma presence in 24 patients (28.6%), violation 
of gastro-intestinal (GI) tract in 6 patients (7.1%), small bowel resection 
with anastomosis in 1 patient (1.2%), take down of ileostomy with 
ileocolonic anastomosis in 2 patients (2.4%), cholecystectomy in 1 pa-
tient (1.2%), creation of stoma in 3 patients (3.6%), or other reasons in 4 
patients (4.8%). One patient was proven to be contaminated with 
extended spectrum beta-lactamase bacteria, but did not meet any of the 
criteria for a VHWG grade 3. After inclusion, two patients were 
considered to have Grade 4 hernias instead of Grade 3 due to the pres-
ence of an active infection (1; 1.2%) and a fistula (1; 1.2%). However, 
they remained included in the analyses. 
Hernia characteristics can be found in Table 3. One of these charac-
teristics is the CDC wound classification [21]. This is not to be confused 
with the VHWG grading system; with the CDC wound classification, the 
wound site is assessed as either clean, clean-contaminated, contaminated, 
or infected. The frequency of the use of CST is shown, because CST use in 
the treatment for incisional hernia repair might lead to more post-
operative surgical complications compared to a Rives-Stoppa technique. 
Concomitant procedures included, among others, lysis of adhesions, 
relocation of a colostomy, hemicolectomy, removal of excess skin, or 
Hartmann reversal. All hernias were located in the midline. 
3.3. SSO rate 
The primary outcome measure, SSO rate, is listed in Table 4. In total, 
22 patients (26.2%; 95% CI: 17.2%–36.9%) developed 32 SSOs. Four of 
the SSOs (12.5%) required hospitalization, 3 required surgical inter-
vention (9.3%), 1 required an ultrasound examination before drainage 
(3.1%), 1 required a vacuum assisted closure device (3.1%), 2 were 
resolved by aspiration (6.3%), 1 superficial excision of necrotic tissue 
took place (3.1%), and twenty SSOs (62.5%) could be managed with 
Table 2 
Baseline characteristics (mean (SD) or n (%)).   
N = 84 
Gender  
Male (%) 51 (60.7) 
Female (%) 33 (39.3) 
Age, years (SD) 62.5 (12.4) 
BMI, kg/m2 (SD) 27.8 (4.0) 
History of post-surgical infection (%) 60 (71.4) 
Hypertension (%) 39 (46.4) 
Smoking (%) 39 (46.4) 
Cancer history (%) 35 (41.7) 
Lung disease (%) 19 (22.6) 
Cardiovascular disease (%) 19 (22.6) 
Diabetes Mellitus (%) 12 (14.3) 
Renal disease (%) 12 (14.3) 
Chronic pain (%) 10 (11.9) 
Kg/m2: kilogram per square meter, SD: standard deviation, BMI: Body 
Mass Index. 
Table 3 
Hernia characteristics (mean (SD) or n (%)): size, site contamination according 
to CDC classification, and surgical methods.  
Hernia defect N = 84 
Length in cm (SD) 12.1 (5.7) 
Width in cm (SD) 8 (3.5) 
Size in cm2 (SD) 109.2 (87.9) 
CDC Wound Class – Preoperative Assessment  
Clean (%) 1 (1.2) 
Clean-contaminated (%) 46 (54.8) 
Contaminated (%) 37 (44.0) 
CDC Wound Class –  
Assessment at Device Implant  
Clean (%) 35 (41.7) 
Clean-contaminated (%) 38 (45.2) 
Contaminated (%) 10 (11.9) 
Dirty/Infected (%) 1 (1.2) 
Surgical details  
Retro-rectus with CST (%) 48 (57.1) 
Retro-rectus without CST (%) 35 (41.7) 
Onlay, with CST (%) 1 (1.2) 
Concomitant procedures (%) 52 (61.9) 
In case of CST  
Ramirez/open technique (%) 13 (27.1) 
Posterior CST (%) 16 (33.3) 
Endoscopic/minimally invasive technique (%) 12 (25.0) 
Combination of techniques 7 (14.6) 
SD: standard deviation, CST: component separation technique. 
Table 4 
SSO rates, split up for the use of component separation technique and preop-





















9 (25.7) 9 (23.7) 13 (28.9) 
Total SSO 32 20 12 15 17 
SSI 11 8 3 6 5 
Wound 
dehiscence 
9 6 3 5 4 
Seroma 7 4 3 3 4 
Hematoma 2 – 2 – 2 
Skin necrosis 2 2 – – 2 
Fistula 1 – 1 1 – 
SSO: surgical site occurrence, SSI: surgical site infection, CST: component sep-
aration technique, Contam.: contaminated, Clean-contam.: clean-contaminated. 
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either medication, wound care, or drainage alone. 
Patients with SSOs were stratified for the use of CST and for either 
contaminated or clean-contaminated wound sites. With regard to the 
difference of SSO development per sex, among men 19.6% developed an 
SSO, compared to 36.4% among women. 
A total of 90 adverse events (AE) were experienced by 43 patients 
(51.2%). SSOs were also considered AEs. AEs that were not SSOs, were, 
for example, postoperative ileus, hypokalemia, or pneumonia. In 2 pa-
tients, the AE was considered to be possibly device-related; these were a 
seroma and a parastomal hernia recurrence. In the other patients the AE 
was not device-related. Of the 90 AEs, 28 were serious adverse events 
(SAE), in 16 patients (19.0%), all of which were classified as not device- 
related. One Phasix™ Mesh had to be explanted due to the patient’s 
development of fecal peritonitis two days after surgery. No clinical 
hernia recurrences of the hernias repaired with Phasix™ Mesh occurred 
within 3 months. 
4. Discussion 
Phasix™ Mesh demonstrated acceptable postoperative SSO rates for 
VHWG Grade 3 incisional hernia repair in the short term. An SSO rate of 
26% is rather low in this patient population. The reported SSO rate in 
VHWG grade 3 hernias when synthetic mesh is used, is between 6% and 
55% [22,25–29]. The 6% comes from a study in which only 17 patients 
with VHWG grade 3 were included, and the SSO rate was assessed after 
30 days, whereas in this trial, the SSO rate was assessed after 90 days 
[26]. All other studies reporting an SSO rate in VHWG grade 3 patients 
treated with synthetic mesh, report rates over 30% [22,25,27–29]. 
Studies describing the use of synthetic meshes in contaminated settings 
(not reporting a VHWG grade), observe similar results to ours. One large 
retrospective study of 100 patients using lightweight polypropylene 
mesh showed a 26.2% SSO rate in clean-contaminated cases, and 34% in 
contaminated cases. Also the SSI rate in this study was slightly higher 
than ours, with 14% within 30 days [30]. 
Only few studies have reported the SSO incidence in VHWG grade 3 
patients after repair with biological mesh. One study reports a 63% SSO 
rate in patients with either VHWG grade 3 or 4 [31]. Another study 
compared Permacol®, Surgisis®, and Alloderm®, rendering an SSO rate 
of 25%–40% [32]. However, no information on contamination of the 
hernia site was reported in that study. A recent systematic review on 
biologic versus synthetic mesh in clean-contaminated hernias found 
overall surgical site complication rates of 44% in the nonabsorbable 
synthetic group, and 50% in the biologic group [33]. 
As described above, comparison of the SSO rate between studies is 
difficult, since many different factors play a role in studies, such as type 
of mesh used, the use of a component separation technique, study type 
(prospective or retrospective), and the timeframe used to detect SSOs. 
However, the P4HB biosynthetic mesh from this study seems to show 
acceptable short-term results. 
An interesting finding was the difference in SSO development be-
tween men and women in the study. Women tended to develop SSOs 
more often than men (36.4% vs 19.6%). This difference in SSO might be 
explained by the use of CST between men and women; CST was used in 
40% of men and in 75% of women that developed an SSO. There was no 
difference in contamination of the surgical site between men and 
women. However, due to the small study sample, no conclusions can be 
drawn upon the difference in SSO rate between the sexes. 
As we did an intention-to-treat analysis, two patients were included 
in the analysis while actually having a VHWG grade 4 surgical site. 
These patients both contributed to the SSO rate, with both developing a 
postoperative wound infection (SSI) and wound dehiscence. The actual 
SSO rate in VHWG grade 3 patients would therefore be slightly lower. 
From the results, it can also be confirmed that smoking seems to be a 
risk factor for the development of a superficial or deep infection. Many 
included patients were smokers, and 7 of the 11 patients that developed 
an SSI were current or past smokers (63.6%). 
4.1. Limitations 
A methodological limitation of the study is the absence of a control 
group. However, all comparison options have their own drawbacks. 
First, no standard treatment is registered for VHWG Grade 3 hernias. 
Because 15 hospitals in Europe participated, it would be insufficient to 
use the standard treatment per hospital as a control group. This would 
lead to very heterogeneously treated patients and different results, not 
suitable for the comparison with the performance of the Phasix™ Mesh. 
Second, permanent synthetic mesh could have been used in a control 
group, because it reduces recurrences when compared to suture closure 
or closure with the aid of biological mesh [34,35]. However, due to the 
potential contamination in VHWG Grade 3 hernias, synthetic mesh 
could lead to a high infection and potential removal rate [36,37]. Last, 
using biological mesh in the control group is also not ideal. Biological 
mesh has the advantage of having a high salvage rate when infected [38, 
39], but renders a higher recurrence rate than repair with synthetic 
mesh [35]. 
Another methodological limitation might be the partially standard-
ized procedure for incisional hernia repair in this study. Multiple centers 
in multiple countries across Europe participated. Every center or every 
surgeon has different regulations, habits, and preferences. Because of 
the patient population, some centers use CST more often than others. 
CST use in the treatment for incisional hernia repair might lead to more 
postoperative surgical complications, compared to exclusive use of a 
sublay technique (24% vs. 11.1%) [40]. However, the SSO rates for both 
patients treated with and without CST were not significantly different in 
the present study. This finding might be explained by the fact that all 
patients were treated in experienced hernia centers across Europe, and 
that some freedom in the surgical protocol should be allowed to provide 
the most fitting repair for every individual patient. 
5. Conclusion and implications 
Phasix™ Mesh demonstrated acceptable post-operative surgical site 
occurrence rates for VHWG Grade 3 incisional hernia repair. These re-
sults on infection and complications rates are valuable for the surgeon in 
the decision to use this new and promising type of mesh for hernia repair 
in this high-risk patient group. However, it remains to be studied 
whether hernia repair with Phasix™ Mesh causes lower recurrence rates 
and is more cost-effective than the use of biologics or permanent syn-
thetics. Due to the high rate of obesity and comorbidities present in the 
studied population, the anticipated recurrence rate is high [2,3,41]. A 
low recurrence rate after longer follow-up would stimulate surgeons to 
consider the use of a biosynthetic mesh in potentially contaminated 
hernias. Cost-effectiveness analysis could also be valuable when 
long-term results are available, as recurrence and reoperation are both 
costly, but occur frequently later than only 3 months after surgery. Aside 
from complications, surgical site occurrences, and recurrences, the 
course of quality of life in patients receiving repair with Phasix™ Mesh 
should also be assessed. In short, information on the long-term perfor-
mance of Phasix™ Mesh should be collected to make real recommen-
dations regarding its use, but the early results are promising. This study 
is ongoing through 24 months of follow-up. 
Ethical Approval 
The protocol was reviewed and approved by the Institutional Review 
Boards or Health Authorities of all participating centers. 
Sources of funding 
Davol Inc. (subsidiary of C.R. Bard, Inc.; part of Becton Dickinson 
since 01-Jan-2018; the sponsor). 
M.MJ. van Rooijen et al.                                                                                                                                                                                                                      
International Journal of Surgery 83 (2020) 31–36
35
Author contribution 
Study conception and design: Jairam, Jeekel. 
Acquisition of data: van Rooijen, Kroese, Tollens, Jørgensen, de Vries 
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Reilingh, Piessen, Köckerling, Miserez, Windsor, Berrevoet, Fortelny, 
Dousset, Woeste, van Westreenen, Gossetti, Lange, Tetteroo, Koch. 
Research Registration Number 
1. Name of the registry: Clinicaltrials.gov 
2. Unique Identifying number or registration ID: NCT02720042 
3. Hyperlink to your specific registration (must be publicly accessible and 
will be checked): https://www.clinicaltrials.gov/ct2/show/NCT027200 
42?term=Phasix&cond=Incisional+Hernia&rank=5. 
Guarantor 
Prof. dr. J. Jeekel. 
Provenance and peer review 
Not commissioned, externally peer-reviewed. 
CRediT authorship contribution statement 
Mathilde MJ. van Rooijen: Acquisition of data, Formal analysis, 
Drafting, of manuscript. An P. Jairam: Study concept. Tim Tollens: 
Acquisition of data, Critical revision. Lars N. Jørgensen: Acquisition of 
data, Critical revision. Tammo S. de Vries Reilingh: Acquisition of 
data, Critical revision. Guillaume Piessen: Acquisition of data, Critical 
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